-
-
-
-
-
-
-
Karyopharm (KPTI) Confirms Panel Recommended FDA Wait for Results from Phase 3 BOSTON Study of Selinexor in Patients R/R MM before Making Final Decision on Approval
-
-
-
-
-
-
-
Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
-
-
-
-
-
-
15,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

